Development of a Potency Assay for Nous-209, a Multivalent Neoantigens-Based Genetic Cancer Vaccine

Development of a Potency Assay for Nous-209, a Multivalent Neoantigens-Based Genetic Cancer Vaccine

Quality control testing of vaccines, including potency assessment, is critical to ensure equivalence of clinical lots. We developed a potency assay to support the clinical advancement of Nous-209, a cancer vaccine based on heterologous prime/boost administration of two multivalent viral vector produ...

Full description

Bibliographic Details
Main Authors: Rosa Bartolomeo, Fulvia Troise, Simona Allocca, Giulia Sdruscia, Rosa Vitale, Veronica Bignone, Anna Maria Petrone, Giuseppina Romano, Anna Morena D’Alise, Valentino Ruzza, Irene Garzia, Guido Leoni, Rossella Merone, Francesca Lanzaro, Stefano Colloca, Loredana Siani, Elisa Scarselli, Gabriella Cotugno
Format: Article
Language:English
Published: MDPI AG 2024-03-01
Series:Vaccines
Subjects:
viral vectors
quality control testing
potency assessment
cancer vaccine
RT-Q-PCR potency assay
synthetic polypeptides
Online Access:https://www.mdpi.com/2076-393X/12/3/325

Similar Items

Similar Items